AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06057220 — intervention group
Intervention type: OTHER
Intervention: No intervention sample collection only
Description: No intervention
Study NCT05227313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eefooton oral solution
Description: Eefooton is extracted from Rhodiola, Huang Qi, American Ginseng, Dang Ginseng, and Ligustrum lucidum by biotechnology. It has immunomodulatory effects, anti-oxidation and anti-inflammatory effects, and regulates calcium metabolism.
Study NCT05227313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Eefooton oral solution
Description: Eefooton is extracted from Rhodiola, Huang Qi, American Ginseng, Dang Ginseng, and Ligustrum lucidum by biotechnology. It has immunomodulatory effects, anti-oxidation and anti-inflammatory effects, and regulates calcium metabolism.
Study NCT05227313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo oral solution
Description: oral solution matched placebo
Study NCT05227313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral solution
Description: oral solution matched placebo
Study NCT04935593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The RENEW Intervention
Description: An game-based intervention that will provide lessons and activities in social-awareness, self-management, self-awareness, relationships and decision making in effort to strengthen social, emotional and behavioral competence. The intervention will be administered tri-weekly for 20 minutes each session.
Study NCT05756426 — intervention group
Intervention type: OTHER
Intervention: Prospective
Description: Single arm, healthy adult volunteers for blood donation.
Study NCT05794373 — intervention group
Intervention type: PROCEDURE
Intervention: Standard physiotherapy for low back pain in a municipality setting
Description: Patients (N=100) referred to a municipality-based rehabilitation for low back pain are included. The physiotherapists choose the rehabilitation strategy based on what they consider relevant for the patients. After the first 100 patients have been discharged from municipality care, the physiotherapists will participate in an educational intervention (12 sessions) focusing on the management of low back pain within a multidimensional framework. In the educational intervention, the participants will learn how to identify the presence of unhelpful thoughts and emotions and how to address these as part of the intervention. The course will thus be a mix of theoretical and practical teaching, including case supervision and feedback. Following the educational intervention, an additional 100 patients referred to the rehabilitation program will be included. The intervention is aimed at the physiotherapists where the patients will receive the best available care, before or after the intervention.
Study NCT05360277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab + Capecitabine
Description: Tislelizumab 200mg iv every 3 weeks, for 1 year after completion of perioperative chemotherapy.~Capecitabine was given at a dose of 850 mg/m2 twice a day by mouth, 2 weeks on/ 1 week off, for 1 year after completion of perioperative chemotherapy.
Study NCT05360277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care
Description: Best supportive care
Study NCT06200948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
Study NCT06200948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete Decongestive Treatment
Description: While the patients in non-cycling group will get only complete decongestive treatment (CDT) for 3 weeks, the patients in cycling group will get CDT+cycling ergometry treatment for 3 weeks. Cycling ergometry treatment will be performed with Voit AT-200 Black Collection horizontal bike for 20 minutes. Exercise intensity will be adjusted to %40-59 of heart rate reserve (HRR).
Study NCT05887232 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser
Description: Patient in group A received FCL treatments four sessions with four weeks apart
Study NCT05887232 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 with Platelet Rich Plasma
Description: Group B received four PRP and FCL sessions 4 weeks apart
Study NCT04685967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glass ionomer
Description: Equia Forte HT, GC, Tokyo, Japan
Study NCT04685967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bulk-fill composite
Description: SonicFill2, Orange, CA, USA
Study NCT04515173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial intelligence diagnosis and treatment assistance system
Description: An artificial intelligence robot that can assist psychiatrists in disease screening, diagnosis, treatment, and follow-up.
Study NCT04515173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Artificial intelligence diagnosis and treatment assistance system
Description: An artificial intelligence robot that can assist psychiatrists in disease screening, diagnosis, treatment, and follow-up.
Study NCT05551117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine 2.0 mg (Arm A)
Description: 2.0 mg/kg intravenous (IV) every 4 weeks
Study NCT05551117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine 2.7 mg (Arm B)
Description: 2.7 mg.kg IV every 4 weeks
Study NCT05551117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vobramitamab duocarmazine
Description: 2.7 mg.kg IV every 4 weeks
Study NCT05108376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visensia Safety Index (VSI)
Description: Enrolled patients will undergo continuous vital sign monitoring, to be used by the Visensia Safety Index (VSI) to identify early deterioration. If early deterioration is identified, the VSI will produce an alert to notify the RACE team.
Study NCT03215459 — intervention group
Intervention type: DEVICE
Intervention: Cardiopulmonary Exercise Test
Description: Cardiopulmonary Exercise Test
Study NCT04888949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell
Description: 1\*10\^8 cells are administered once a week, total four times intravenously.
Study NCT04888949 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available saline.
Study NCT05551117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: 1000 mg once daily
Study NCT05551117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: 160 mg daily
Study NCT04695366 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05824091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7762 (TBD09)
Description: Cohort 1: 50 mg Cohort 2: 150 mg Cohort 3: 300 mg Cohort 4: 600 mg Cohort 5: TBD Cohort 6: TBD
Study NCT05824091 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A subset of participants from each of the 6 dosing cohorts will receive placebo.
Study NCT05602350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administered survey
Description: Subjects will self-administer questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
Study NCT05602350 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enumerator-administered survey
Description: Subjects will have enumerator-administered questionnaire sections on sensitive topics: (1) antisocial behaviors, (2) symptoms of depression, and (3) symptoms of anxiety.
Study NCT04676698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three Good Things
Description: The treatment phase will last 3 weeks. However, participants will complete surveys at baseline and up to 6 months. At the end of the trial the study team will also select a limited number of entries from participants to share some of the good things which people listed. These will be edited to ensure writer anonymity and participants will be informed of this plan in the study introduction.
Study NCT04676698 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait list control arm and then Three Good Things
Description: Surveys will be completed for 3 months prior to treatment and then after treatment.
Study NCT06287190 — intervention group
Intervention type: OTHER
Intervention: Dental interns
Description: Assessing self-assessment
Study NCT04956926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS201
Description: JS201 is administered intravenously Q3W at the corresponding dose.
Study NCT06137560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single vision spectacle lens
Description: Standard single vision spectacle lens
Study NCT06137560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single vision spectacle lens + S.T.O.P.® Kit 1
Description: Standard single vision spectacle lens + S.T.O.P.® Kit 1
Study NCT06137560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single vision spectacle lens + S.T.O.P.® Kit 2
Description: Standard single vision spectacle lens + S.T.O.P.® Kit 2
Study NCT06137560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single vision spectacle lens + S.T.O.P.® Film
Description: Standard single vision spectacle lens + S.T.O.P.® Film
Study NCT06137560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2
Description: Standard single vision spectacle lens + S.T.O.P.® Kit 1 or 2
Study NCT05960942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol combined with esketamine
Description: In group PE, esketamine was firstly administered at a dose of 0.3 mg.kg-1, followed immediately by propofol with a single intravenous dose of 2.0 mg.kg-1.
Study NCT05960942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol-sufentanil
Description: In group PS, sufentanil was administered intravenously at a dose of 0.2 μg.kg-1, then 2.0 mg.kg-1 propofol was intravenously injected.
Study NCT05017285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HoLEP with median lobe preservation
Description: Enucleation of the lateral lobes and preservation of the medial tissue between the bladder neck and Veru montanum
Study NCT05017285 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: HoLEP classic
Description: Standard HoLEP prostate resection procedure with enucleation of all three lobes (3-lobe, 2-lobe or monobloc technique).
Study NCT04409795 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin Extended Release Oral Tablet
Description: Initial oral hypoglycemic agent added to existing insulin treatment
Study NCT04409795 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: Secondary oral hypoglycemic agent added to existing insulin treatment (for those who are intolerant to or unable to achieve glycemic targets with metformin)
Study NCT06472258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Artesunate
Description: IV artesunate with a weight-appropriate dosage at 0, 12, 24, and 48 hours and continued 12-hourly for a maximum duration of seven days, with each dose diluted in normal saline and given as an infusion.
Study NCT06472258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Quinine Hydrochloride
Description: IV Quinine hydrochloride in accordance to weight with loading dose 20mg salt/kg in 10% dextrose infusion followed by 10mg salt/kg infusion 8 hourly for 2 days and for 12 hourly onwards for a maximum of 7 days.
Study NCT06555692 — intervention group
Intervention type: BIOLOGICAL
Intervention: Transplant acellular dermal matrix(ADM)
Description: The principle of surgery is the pectoral muscle preservation (prepectoral) method and the subpectoral method (Breast Reconstruction using implants). After wrapping the implant with acellular dermal matrix(ADM), it is inserted into the breast and fixed to the underlying muscle or surrounding tissue depending on the situation.
Study NCT05300867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurorehabilitation
Description: Neurorehabilitation with soft exsoskeleton robotic 3-week-long
Study NCT05300867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy 3-week-long
Study NCT06557915 — intervention group
Intervention type: PROCEDURE
Intervention: screening
Description: screening and detection of nasal problems in Neonates and Infants Subjected to CPAP
Study NCT04925908 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR for SARS-Cov-2
Description: Nasopharyngeal swab for detecting Novel Coronavirus-2 by reverse transcriptase polymerase chain reaction
Study NCT06496464 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Phase 1 MASTER Coach Development Workshop (weeks 1) PE teachers participated in a 6-hour theory and practical teacher education workshop to a research team (JY) member, including 4h of reading relevant papers and books regarding the game-based approach (GBA) .~Phase 2 Eight weeks of teaching mentoring (weeks 2-7) This 8-week phase involved coaches implementing MASTER elements (e.g. 10-minute stretching before a sports game, teachers will give 1-2 sentences of praise during the game for individual students who make a reasonable effort) in their regular training sessions.~Phase 3 3 weeks peer assessed teaching/discussions (weeks 8-10) The mentor prepared and implement a 2-h training session designed to highlight important aspects of the MASTER framework and games-based coaching practices.
Study NCT06496464 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intervention
Description: Phase 1 MASTER Coach Development Workshop (weeks 1) PE teachers participated in a 6-hour theory and practical teacher education workshop to a research team (JY) member, including 4h of reading relevant papers and books regarding the game-based approach (GBA) .~Phase 2 Eight weeks of teaching mentoring (weeks 2-7) This 8-week phase involved coaches implementing MASTER elements (e.g. 10-minute stretching before a sports game, teachers will give 1-2 sentences of praise during the game for individual students who make a reasonable effort) in their regular training sessions.~Phase 3 3 weeks peer assessed teaching/discussions (weeks 8-10) The mentor prepared and implement a 2-h training session designed to highlight important aspects of the MASTER framework and games-based coaching practices.
Study NCT05207839 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk powder
Description: one sachet per day dissolved in 200 ml of water
Study NCT05207839 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk powder
Description: one sachet per day dissolved in 200 ml of water
Study NCT06637189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix
Description: Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitively binding to GnRH receptors in the pituitary gland. Consequently, there is a reversible, intense, and rapid suppression of endogenous gonadotropin release. Ganirelix is indicated for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive techniques (ART).
Study NCT06637189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone Acetate 10 MG
Description: Medroxyprogesterone acetate is a synthetic progestin (structurally related to progesterone) with antiestrogenic, antiandrogenic, and antigonadotropic action. It inhibits pituitary gonadotropins (FSH and LH) with consequent inhibition of follicular maturation and ovulation . Medroxyprogesterone acetate is active orally and parenterally, 15 times more potent than progesterone. In addition to inhibiting ovulation, progestins also act on the endometrium preventing implantation and increasing the viscosity of cervical mucus, which hinders sperm progression in the uterus. It also transforms a proliferative endometrium into a secretory endometrium, provided that the woman has adequate endogenous estrogen levels.
Study NCT05966714 — intervention group
Intervention type: DEVICE
Intervention: NIRS
Description: cerebral oxygenation and electrical activity monitoring
Study NCT05966714 — intervention group
Intervention type: DEVICE
Intervention: aEEG
Description: amplitude-integrated electroencephalography
Study NCT06639802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Arm Bimanual Intensive therapy including lower extremity (HABIT-ILE)
Description: HABIT-ILE is continuous intervention applied for 50-90 hours over two weeks. We will design the activities based on the findings of the initial assessments (T0) and the customized functional goals that were previously discussed with the parents (e.g., drinking on one\&#39;s own without spilling, using one hand to hold a book while turning pages with the other, removing a t-shirt, etc.). HABIT-ILE activities are presented as games and the whole environment is arranged in such a way that children perceive the therapy as fun. Progression of difficulty depend upon success in performance of current level. Specific bi-manual activities are selected on basis of child's motor abilities, age and interest.
Study NCT06638190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 100% Orange juice
Description: 250 mL of commercial 100% orange juice containing 25 g of total sugars (glucose, fructose, saccharose).
Study NCT06638190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50% Orange juice
Description: 250 mL of 50% diluted orange juice (100% orange juice) plus added sugars to attain the same concentration and composition of sugars (glucose, fructose, saccharose) as the 100% orange juice
Study NCT06638190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0% Orange juice
Description: 250 mL of water plus added sugars to attain the same concentration and composition of sugars (glucose, fructose, saccharose) as the 100% orange juice
Study NCT06638190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 250 mL of water with 25 g of glucose. To determine the glycemic index of the different drinks and to characterize the glucose and insuline response of the participants
Study NCT06638190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 100% Orange juice Rep
Description: Repetition of the 100% orange juice intervention
Study NCT06638190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0% Orange juice Rep
Description: Repetition of the 0% orange juice intervention
Study NCT06641492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chatbot-delivered interventions tailored to one's stage of changes
Description: The Chatbot will assess participants' physical activity level and stage of changes regarding physical activity and automatically deliver interventions tailor to their stage of changes every week for 12 weeks. The Chatbot will address questions related to physical activity raised by the participants.
Study NCT06641492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chatbot-delivered standard interventions
Description: The Chatbot will not assess participants' stage of changes. It will assess participants' physical activity level and provides a standard intervention covering general information about physical activity for older adults, which is not tailoring to participants' stage of changes every week for 12 weeks. The Chatbot will address questions related to physical activity raised by the participants.
Study NCT06439810 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mycobacterium tuberculosis (MTB) cell-free DNA (cfDNA)
Description: Comparing the diagnostic accuracy between MTB cfDNA and PCR on diagnosing tuberculous pleuritis
Study NCT06561776 — intervention group
Intervention type: OTHER
Intervention: Physical Evaluations of individuals
Description: Participants will be evaluated on cough strength, physical activity and balance. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
Study NCT06642129 — intervention group
Intervention type: PROCEDURE
Intervention: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
Description: Lumboperitoneal shunt (LPS) involves connecting the subarachnoid space of the lumbar spine to the peritoneal cavity through a pressure-adjustable unidirectional valve to shunt the appropriate amount of cerebrospinal fluid from the ventricles to the peritoneal cavity via the spinal canal, where it is absorbed through the peritoneum, to alleviate the increased intracranial pressure caused by the communicating hydrocephalus and the corresponding clinical symptoms.
Study NCT06640231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sealer activation after cleaning and shaping with XP-Endo Finisher
Description: activation of sealer before the obturation of root canals
Study NCT06640231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: negative control where canals are obturated directly without sealer activation
Description: sealer after cleaning and shaping before the obturation without using activation method
Study NCT06637774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspirometer
Description: a triaxial accelerometer and a contact microphone affixed with tape to patient neck, a data accrual infrastructure, algorithms that decode swallow physiology noninvasively